Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FGF1
REST API REST API
Homo sapiens
FGF1 is differentially expressed in 247 experiments: 205 organism parts: bone marrow, cerebellum, ... (203 more);, 194 disease states: normal, Parkinson's disease, ... (192 more);, 81 cell types 204 cell lines 24 compound treatments and 72 other conditions.
Synonyms ECGFA, ECGFB, GLIO703, ECGF, HBGF1, ECGF-beta, FGF-alpha, FGFA, AFGF
Orthologs FGF1_BOVIN (Bos taurus)   Fgf1 (Rattus norvegicus)   Q8I6J4_CIOIN (Ciona intestinalis)   Fgf1 (Mus musculus)   FGF1_CHICK (Gallus gallus)   fgf1 (Danio rerio)   fgf1b (Danio rerio)   fgf1 (Xenopus laevis)   FGF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, positive regulation of cell division, protein binding, cytoplasm, cell cortex, extracellular space, positive regulation of cell proliferation, heparin binding, proteinaceous extracellular matrix, growth factor activity, protein tyrosine kinase activity, extracellular region, insulin receptor signaling pathway, fibroblast growth factor receptor signaling pathway, cell differentiation, positive regulation of transcription from RNA polymerase II promoter, fibroblast growth factor receptor binding, anatomical structure morphogenesis, multicellular organismal development, nucleus, nervous system development, cellular response to heat, signal transduction, nucleolus, intracellular protein kinase cascade, positive regulation of cell adhesion, positive regulation of cholesterol biosynthetic process, positive regulation of intracellular protein kinase cascade, positive regulation of cell migration, positive regulation of epithelial cell proliferation, S100 alpha binding, lung development, positive regulation of angiogenesis, positive regulation of protein phosphorylation, organ induction
InterPro Term IL1_HBGF, GF_heparin-bd
UniProt Accession P05230, Q9UBK1, Q6LBM3, B5MCF4, C9JDC5, A8K147, C9JUP6, E7ET74
Search EB-eye ENSG00000113578
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
PC3
2
E-GEOD-5258, E-MEXP-2034
Caco-2
1
E-GEOD-1474
T84
1
E-GEOD-1474
DMS273
1
E-MTAB-37
HPL1
1
E-TABM-420
198 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22373, E-GEOD-3920, E-MEXP-66, E-GEOD-13987, ... (41 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
stromal cell
1
2
E-GEOD-1460, E-MEXP-2034, E-GEOD-10797
SVGR2
1
E-GEOD-7819
induced pluripotent stem cell
1
E-GEOD-18265
75 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (57 experiments)

Factor Value U/D Experiments
Wilms tumor
2
E-MTAB-37, E-GEOD-2712
colon carcinoma
2
E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
monoclonal gammopathy of uncertain significance
1
E-MTAB-372
squamous cell cancer
1
E-MTAB-62
188 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-5824, E-MEXP-2417, E-MEXP-2590, ... (14 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-5824, E-GEOD-412, E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
NaOH
1
E-MEXP-2590
ponasterone A
1
E-GEOD-3113
Ethanol
1
E-MEXP-2417
unknown
1
E-GEOD-7307
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847, E-MTAB-108, E-GEOD-361, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-6432, E-MEXP-1446, E-GEOD-9764, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-MEXP-1956, E-GEOD-1926, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-1493, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-GEOD-1561

Processing time: 0.271 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM